Clinical Trial Update: Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type [Phase 2]

View source ↗

Summary

Phase 2 trial of panitumumab plus pegylated liposomal doxorubicin for platinum-resistant epithelial ovarian cancer with KRAS wild-type has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer

Drugs mentioned

• Panitumumab (panitumumab)
• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)

Snippet

Sponsor: Vejle Hospital | Conditions: Epithelial Ovarian Cancer | Phase 2 | Status: COMPLETED